FEB 20 1985

License No. 20-02215-01
Docket No. 030-01845
Control No. 03195

Boston University Medical Center
ATTN: Victor Evdokimoff, M.S., C.H.P.
Radiation Protection Officer
720 Harrison Avenue
Boston, Massachusetts 02118

Gentlemen:

Please find enclosed an amendment to your NRC Material License.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the Region I Material Licensing Section, (215) 337-5239, so that we can provide appropriate corrections and answers.

Please be advised that you must conduct your program involving licensed radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, please note the items in the enclosed, "Requirements for Materials Licensees."

The enclosed amendment responds to the first three paragraphs of your letter dated December 3, 1984. With respect to the fourth paragraph of that letter requesting authorization to receive radioactive waste from other persons for disposal by incineration, additional information is needed before we can act. The request will then be referred to headquarters for action.

We need more detailed information on the relationship between Boston University Medical Center and the institutions sending the waste, and the financial transactions involved. The importance of this information becomes apparent when one recognizes that a license authorizing commercial incineration of waste involves a fee of $803,700 (Category 4A, 10 CFR Part 170), official notification of municipal authorities (10 CFR Part 2), and the preparation of an environmental impact statement. Whether any of this will be necessary will be determined by NRC headquarters, based on your response to these questions.

Please send your reply in duplicate to my attention, and reference Mail Control Number 03195.

Since serious consequences to employees and the public can result from failure to comply with NRC requirements, the NRC expects licensees to pay meticulous attention to detail and to achieve the high standard of compliance which the NRC expects of its licensees.

OFFICIAL RECORD COPY 20-02215-01/LTR - 0001.0.0
02/09/85

NL1D

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

OFFICIAL RECORD COPY

Licensee

1. Boston University Medical Center

2. 720 Harrison Avenue
Boston, Massachusetts 02118

In accordance with letter dated December 3, 1984
3. License number 20-02215-01 is amended in its entirety to read as follows:

4. Expiration date April 30, 1985

5. Docket or Reference No. 030-01845

6. Byproduct source and special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 5 curies of each byproduct material authorized in Subitem 9.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 200 millicuries total for sources authorized in Subitem 9.E.
F. Xenon 133	F. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	F. 400 millicuries

NRC FORM 374
20-02215-01 PDR

ML10

MATERIALS LICENSE
SUPPLEMENTARY SHEET

(continued)

A. Byproduct, source, and/or special nuclear material	B. Chemical and/or physical form	C. Maximum amount that licensee may possess at any one time under this license
G. Any byproduct material between Atomic Nos. 3 and 83 inclusive, except as below	G. Any	G. 300 millicuries of each
H. Calcium 45	H. Any	H. 200 millicuries
I. Carbon 14	I. Any	I. 300 millicuries
J. Chromium 51	J. Any	J. 300 millicuries
K. Phosphorus 32	K. Any	K. 300 millicuries
L. Iodine 125	L. Any	L. 300 millicuries
M. Iodine 131	M. Any	M. 400 millicuries
N. Strontium 89	N. Any	N. 200 millicuries
O. Hydrogen 3	O. Any	O. 5 curies
P. Americium 241	P. Sealed source	P. 4 millicuries
Q. Hydrogen 3	Q. Sealed source	Q. 25 curies
R. Nickel 63	R. Sealed source	R. 45 millicuries
S. Cesium 137	S. Sealed source	S. 10 millicuries
T. Uranium (depleted in Uranium 235)	T. Ceramic plated metal	T. 135 kilograms
U. Iodine 125	U. Sealed source (Amersham Model [illegible] or AECL C-32[illegible])	U. Not to exceed 500 millicuries per source
V. Cesium 137	V. Sealed sources (AECL Model C-161 Type 6)	V. Two sources not to exceed 2000 curies per source

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
F. Blood flow and pulmonary function studies.
G. through S. Medical diagnosis, therapy, Research and development as defined in 10 CFR 30.4(q), including medical research with humans, animal studies
T. For use as shielding in a linear accelerator.
U. For use in Lixi Inc. Model LI-ROI, LI 602, LIM 602 or LIM 602 portable fluoroscopes for research and development as defined by 10 CFR 30.4(q), animal studies. Human use is excluded.
V. For use in AECL Gammacell 40 irradiator

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 OF 4 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-00215-03
Docket or Reference number: 030-01145
Amendment No. 39

(continued) CONDITIONS

9. Licensed material shall be used only at 720, 750, and 760 Harrison Avenue, Boston, Massachusetts; 75, 80, 85, and 100 East Newton Street, Boston, Massachusetts; 80 and 82 East Concord Street, Boston, Massachusetts; and 615 Albany Street, Boston, Massachusetts.

10. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

11. A. Licensed material shall be used by, or under the supervision of, individuals designated by the Radioisotopes Committee, B. A. Burrows, M.D., Chairman.

B. The use of licensed material in or on humans shall be by a physician as defined in 10 CFR 35.3(b).

C. Physicians designated to use licensed material on or in humans shall meet the training and experience criteria established in Appendix A of Regulatory Guide 10.8 (Revision 1), dated October 1980.

D. The Radiation Protection Officer for the activities authorized by this license is Victor N. Evdokimoff, M.S., CHP.

12. Licensed material in Items 6.A. through 6.E. shall be used in accordance with the provisions of Section 35.24(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

13. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.

14. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.

B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-[illegible]-01
Docket or Reference number: 030-01845

Amendment No. 39

(continued) CONDITIONS

16. A. (1) Each sealed source acquired from another person and containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for contamination and/or leakage prior to use. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

(3) Except for alpha sources, the periodic leak test required by this condition does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within six months prior to the date of use or transfer.

B. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to use or transfer as a sealed source. If the inspection or test reveals any construction defects or 0.005 microcurie or greater of contamination, the source shall not be used or transferred as a sealed source until it has been repaired, decontaminated and retested.

C. Each sealed source containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six months except that each source designed for the purpose of emitting alpha particles shall be tested at intervals not to exceed three months.

D. If the test required by Subsection A. or C. of this condition reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the test with the U.S. Nuclear Regulatory Commission, Region 1, 631 Park Avenue, King of Prussia, Pennsylvania 19406, describing the equipment involved, the test results, and the corrective action taken.

17. Pursuant to Sections 20.106(b) and 20.302, 10 CFR 20, the licensee is authorized to dispose of licensed material by incineration provided the gaseous effluent from incineration does not exceed the limits specified for air in Appendix B, Table II, 10 CFR 20. Ash residues may be disposed of as ordinary waste provided appropriate surveys pursuant to Section 20.201 are made to determine that concentrations of licensed material appearing in the ash residues do not exceed the concentrations (in terms of microcuries per gram) specified for water in Appendix B, Table II, 10 CFR 20.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

(continued) CONDITIONS

18. The licensee may transport licensed material or deliver licensed material to a carrier for transport in accordance with the provisions of Title 10, Code of Federal Regulations, Part 71, "Packaging of Radioactive Material for Transport and Transportation of Radioactive Material Under Certain Conditions."

19. A. Detector cells containing titanium tritide foil shall only be used in conjunction with a properly operating temperature control mechanism which prevents foil temperatures from exceeding 225 degrees Centigrade.

B. Detector cells containing scandium tritide foil shall only be used in conjunction with a properly operating temperature control mechanism which prevents foil temperatures from exceeding 325 degrees Centigrade.

20. In lieu of using the conventional radiation caution colors (magenta or purple on yellow background) as provided in Section 20.203(a)(1), Title 10, Code of Federal Regulations, Part 20, the licensee is hereby authorized to label detector cells and cell baths, containing licensed material and used in gas chromatography devices, with conspicuously etched or stamped radiation caution symbols without a color requirement.

21. The licensee shall conduct a physical inventory every six (6) months to account for all sealed sources received and possessed under the license. The records of the inventories shall be maintained for two (2) years from the date of the inventory for inspection by the Commission, and shall include the quantities and kinds of licensed material, location of sealed sources and the date of the inventory.

22. The licensee shall not use licensed material in field applications where activity is released except as provided otherwise by specific condition of this license.

23. Experimental animals administered licensed materials or their products shall not be used for human consumption.

24. Licensed material shall not be used in products distributed to the public.

25. Written instructions in application dated December 20, 1973, as amended April 22, 1974, and application updated received April 5, 1979, shall be followed and a copy of these instructions shall be made available to each individual using or having responsibility for use of the "Gammacell 40". Any changes in these instructions shall have the prior approval of the U.S. Nuclear Regulatory Commission, Region I, Nuclear Materials Safety and Safeguards Branch, 631 Park Avenue, King of Prussia, Pennsylvania 19406.

26. The procedures contained in AEC's instruction manual for the "Gammacell 40" device shall be followed and a copy of this manual shall be made available to each person using or having responsibility for the use of licensed material.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-02215-01
Docket or Reference number: 030-01845
Amendment No. 39

(continued) CONDITIONS

27. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated November 25, 1980; letters dated June 22, 1982, April 15, 1983 including ALARA Program May 4, 1984, and December 3, 1984. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date FEB 20 1985

By Original Signed By
Lawrence J. Brickman, Ph.D.
Nuclear Materials Safety and
Safeguards Branch, Region 1
King of Prussia, Pennsylvania 19406

MATERIALS LICENSE

Amendment No. 37
CORRECTED COPY

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 36, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Boston University Medical Center	In accordance with application dated November 25, 1980,
	3. License number 20-02215-01 is amended in its entirety to read as follows:
2. 720 Harrison Avenue Boston, Massachusetts 02118	4. Expiration date April 30, 1983
	5. Docket or Reference No. 030-01845

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 3 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 2000 millicuries total for sources authorized in Subitem 6.E.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

License number: 20-02215-01

Docket or Reference number: 030-01845

Amendment No. 37

(continued)

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
F. Xenon 133	F. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	F. 300 millicuries
G. Any byproduct material between Atomic Nos. 3 and 83 inclusive, except as below	G. Any	G. 50 millicuries of each
H. Calcium 45	H. Any	H. 200 millicuries
I. Carbon 14	I. Any	I. 300 millicuries
J. Chromium-51	J. Any	J. 300 millicuries
K. Phosphorus 32	K. Any	K. 150 millicuries
L. Iodine 125	L. Any	L. 300 millicuries
M. Iodine 131	M. Any	M. 100 millicuries
N. Strontium 89	N. Any	N. 100 millicuries
O. Hydrogen 3	O. Any	O. 6 curies
P. Americium 241	P. Sealed source	P. 4 millicuries
Q. Hydrogen 3	Q. Sealed source	Q. 25 curies
R. Nickel 63	R. Sealed source	R. 45 millicuries
S. Cesium 137	S. Sealed source	S. 10 millicuries
T. Uranium (depleted in Uranium 235)	T. Cadmium plated metal	T. 136 kilograms
U. Iodine 125	U. Sealed source (Amersham Model IMC.P2 or AECL C-324)	U. Not to exceed 500 millicuries per source

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

License number 20-02215-01

Docket or Reference number 030-01845

Amendment No. 37

(continued)

E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
F. Blood flow and pulmonary function studies.
G. through S. Medical diagnosis, therapy. Research and development as defined by 10 CFR 30.4(q); including medical research with humans; animal studies.
T. For use as shielding in a linear accelerator.
U. For use in Lixi Inc. Model LS-80X, LS 82X, LSM 80X or LSM 82X portable fluoroscope for research and development as defined by 10 CFR 30.4(q); animal studies. Human use is excluded.

CONDITIONS

10. Licensed material shall be used only at 720, 750, and 790 Harrison Avenue, Boston, Massachusetts; 75, 80, 85, and 100 East Newton Street, Boston, Massachusetts; 80 and 82 East Concord Street, Boston, Massachusetts; and 615 Albany Street, Boston, Massachusetts.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material in Items 6.A. through 6.E. shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

13. A. Licensed material shall be used by, or under the supervision of, individuals designated by the Radioisotopes Committee, B. A. Burrows, M.D., Chairman.

B. The use of licensed material in or on humans shall be by a physician as defined in 10 CFR 35.3(b).

C. Physicians designated to use licensed material in or on humans shall meet the training and experience criteria established in Appendix A of Regulatory Guide 10.8 (Revision 1), dated October 1980.

D. The Radiation Protection Officer for the activities authorized by this license is Victor N. Evdokimoff, M.S., CHP.

14. A. (1) Each sealed source acquired from another person and containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for contamination and/or leakage prior to use. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer a sealed source received from another person shall not be put into use until tested.

(14.A. continued) CONDITIONS

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

(3) Except for alpha sources, the periodic leak test required by this condition does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within six months prior to the date of use or transfer.

B. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to use or transfer as a sealed source. If the inspection or test reveals any construction defects or 0.005 microcurie or greater of contamination, the source shall not be used or transferred as a sealed source until it has been repaired, decontaminated and retested.

C. Each sealed source containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six months except that each source designed for the purpose of emitting alpha particles shall be tested at intervals not to exceed three months.

D. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently or semipermanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.

E. If the test required by Subsection A. or C. of this condition reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the test with the U.S. Nuclear Regulatory Commission, Region I, 631 Park Avenue, King of Prussia, Pennsylvania 19406, describing the equipment involved, the test results, and the corrective action taken.

15. Sealed sources containing licensed material shall not be opened.

16. Patients containing Cobalt 60, Cesium 137 or Iridium 192 implants shall remain hospitalized until surveys made with an appropriate radiation detection instr indicate that all implants have been removed. The results of these surveys recorded and maintained for inspection by the Commission for five (5) year time the implants are removed.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

License number 20-02215-01

Docket or Reference number 030-01845

Amendment No. 37

(continued) CONDITIONS

17. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.

18. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.

    B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

    C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

19. Pursuant to Sections 20.106(b) and 20.302, 10 CFR 20, the licensee is authorized to dispose of licensed material by incineration provided the gaseous effluent from incineration does not exceed the limits specified for air in Appendix B, Table II, 10 CFR 20. Ash residues may be disposed of as ordinary waste provided appropriate surveys pursuant to Section 20.201 are made to determine that concentrations of licensed material appearing in the ash residues do not exceed the concentrations (in terms of microcuries per gram) specified for water in Appendix B, Table II, 10 CFR 20.

20. The licensee may transport licensed material or deliver licensed material to a carrier for transport in accordance with the provisions of Title 10, Code of Federal Regulations, Part 71, "Packaging of Radioactive Material for Transport and Transportation of Radioactive Material Under Certain Conditions."

21. A. Detector cells containing titanium tritide foil shall only be used in conjunction with a properly operating temperature control mechanism which prevents foil temperatures from exceeding 225 degrees Centigrade.

    B. Detector cells containing scandium tritied foil shall only be used in conjunction with a properly operating temperature control mechanism which prevents foil temperatures from exceeding 325 degrees Centigrade.

22. In lieu of using the conventional radiation caution colors (magenta or purple on yellow background) as provided in Section 20.203(a)(1), Title 10, Code of Federal Regulations, Part 20, the licensee is hereby authorized to label detector cells and cell baths, containing licensed material and used in gas chromatography devices, with conspicuously etched or stamped radiation caution symbols without a color requirement.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

License number 20-02215-01

Docket or Reference number 030-01845

Amendment No. 37

(continued) CONDITIONS

23. The licensee shall conduct a physical inventory every six (6) months to account for all sealed sources received and possessed under the license. The records of the inventories shall be maintained for two (2) years from the date of the inventory for inspection by the Commission, and shall include the quantities and kinds of byproduct material, location of sealed sources and the date of the inventory.

24. The licensee shall not use licensed material in or on human beings or in field applications where activity is released except as provided otherwise by specific condition of this license.

25. Experimental animals administered licensed materials or their products shall not be used for human consumption.

26. Licensed material shall not be used in products distributed to the public.

27. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated November 25, 1980, and letters dated June 22, 1982, and April 15, 1983, including ALARA Program. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date July 7, 1983

By Original Signed By
John E. Glenn, Ph.D.
Nuclear Materials and Safeguards Branch
Region I
King of Prussia, Pennsylvania 19406